Multi-center, Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Malignancies

Trial Profile

Multi-center, Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs DCC 3014 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Deciphera Pharmaceuticals
  • Most Recent Events

    • 27 Feb 2017 Status changed from planning to recruiting.
    • 20 Apr 2016 According to Deciphera media release, this trial is expected to initiate in the second half of 2016.
    • 20 Apr 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jul 2016, as reported by Deciphera media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top